A Look At Consun Pharmaceutical Group (SEHK:1681) Valuation After Approving A New HK$0.40 Final Dividend

Simply Wall St.05-31

Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025. See our latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639604778?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-31 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639604778","market":"hk","top_or_hot":-1,"title":"A Look At Consun Pharmaceutical Group (SEHK:1681) Valuation After Approving A New HK$0.40 Final Dividend","media":"Simply Wall St.","content":"<div>\n<p>Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/a-look-at-consun-pharmaceutical-group-sehk1681-valuation-aft\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Consun Pharmaceutical Group (SEHK:1681) Valuation After Approving A New HK$0.40 Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Consun Pharmaceutical Group (SEHK:1681) Valuation After Approving A New HK$0.40 Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-31 01:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/a-look-at-consun-pharmaceutical-group-sehk1681-valuation-aft><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/a-look-at-consun-pharmaceutical-group-sehk1681-valuation-aft\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/a-look-at-consun-pharmaceutical-group-sehk1681-valuation-aft","article_id":"2639604778","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/a-look-at-consun-pharmaceutical-group-sehk1681-valuation-aft","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639604778","pubTimestamp":1780160921,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025.\nSee our latest analysis for Consun Pharmaceutical Group.\nThe stock has eased back recently, with the 30 day share price return down 11.32% and the 90 day share price return down 21.22%. However, the 1 year total shareholder return of 40.06% and 3 year total shareholder return of almost 3x suggest longer term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","01681":"康臣药业","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1191":"制药"},"translate_title":"康臣药业集团（SEHK：1681）批准新的0.40港元末期股息后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":0.9,"DCF":1},"content_text":"Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025. See our latest analysis for Consun Pharmaceutical Group. The stock has eased back recently, with the 30 day share price return down 11.32% and the 90 day share price return down 21.22%. However, the 1 year total shareholder return of 40.06% and 3 year total shareholder return of almost 3x suggest longer term momentum has been strong, with the latest HK$0.40 dividend approval likely reinforcing the focus on shareholder returns. If this dividend story has you looking beyond a single stock, it could be a good moment to broaden your search through 130 healthcare AI stocks With Consun Pharmaceutical Group trading at HK$14.18 and reference estimates pointing to a sizeable discount to assessed value, the question is simple: are you looking at an undervalued dividend payer, or has the market already priced in future growth? AdvertisementPrice-to-Earnings of 9.6x: Is it justified? On a P/E of 9.6x with a last close of HK$14.18, Consun Pharmaceutical Group screens as undervalued compared to its peers and the wider pharmaceuticals sector. The P/E ratio compares the share price with earnings per share, so a lower figure can suggest investors are paying less for each unit of profit. For a profitable pharmaceutical company with HK$3,417.36m in revenue and HK$1,078.07m in net income, this measure provides a quick indication of how the market is valuing its earnings power. In this case, the stock trades on a 9.6x P/E, compared with a peer average of 20.6x and a Hong Kong pharmaceuticals industry average of 13.8x, which is a sizeable gap. Relative to an estimated fair P/E of 17.8x, the current multiple is well below that reference point. Explore the SWS fair ratio for Consun Pharmaceutical Group Result: Price-to-Earnings of 9.6x (UNDERVALUED) However, you also need to weigh risks such as the recent share price pullback, as well as any future shifts in demand for its kidney and contrast medium products. Find out about the key risks to this Consun Pharmaceutical Group narrative. Another View: Cash Flows Point to a Bigger Gap While the 9.6x P/E suggests the stock looks cheap, our DCF model presents an even starker picture, with an estimated future cash flow value of HK$47.37 per share compared with the current HK$14.18 price. That gap raises a simple question: is the market being cautious or just too pessimistic? Look into how the SWS DCF model arrives at its fair value. 1681 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Consun Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 209 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this combination of potential upside and clear risks leaves you uncertain, review the data, act promptly and decide where you stand with 5 key rewards and 2 important warning signs Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at a single stock; broaden your watchlist with targeted, high quality ideas.  Spot potential income anchors by reviewing 486 dividend fortresses that aim to pair substantial yields with resilient cash generation. Hunt for quality at a discount by scanning 209 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their strengths. Strengthen your core holdings by assessing the solid balance sheet and fundamentals stocks screener (395 results) and focusing on companies with robust financial footing.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639604778","isCrawlerRequest":true}